samarium has been researched along with zoledronic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahmane, A; de Klerk, JM; Lam, MG; Stevens, WH; van Rijk, PP; Zonnenberg, BA | 1 |
| Morgans, AK; Smith, MR | 1 |
1 review(s) available for samarium and zoledronic acid
| Article | Year |
|---|---|
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid | 2012 |
1 other study(ies) available for samarium and zoledronic acid
| Article | Year |
|---|---|
Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Metabolic Clearance Rate; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radioisotopes; Samarium; Zoledronic Acid | 2008 |